Neocutis is a brand that utilizes Swiss Technology to create products that not only eliminate the visible signs of scarring, but also reduce and reverse the aging process. Swiss Researchers and physicians have patented PSP “Processed Skin Cell Proteins,” the active ingredient exclusively used in Neocutis Skin Care products to produce some of the best results in skin revitalization. It began when researchers and Biologists at the “Laboratoires de Medecine Foetale” at the Medical School of the University Hospital of Lausanne in Switzerland started working with fetal cells back in 1995. They finally discovered the fetal cells could actually repair and revitalize damaged or aged skin cells, and shortly after, they patented the state-of-the-art process. In 2002, experienced business professionals teamed up with the Physicians and Biologists in Switzerland to create Neocutis. They began with a single biopsy of fetal skin tissue and froze it in liquid nitrogen in order to establish a skin cell bank that would sustain and supply the PSP production. In 2004, with the skin cell bank in place and backing of financial investors, Neocutis launched their first product: Neocutis Bio-Restorative Skin Cream in the United States. With success came the growth and creation of Neocutis, Inc. Headquartered in San Francisco, CA, the company continues to push forward and incorporate modern science and technology to bring the best results in the health and beauty field.


In mid-2013, it was announced that Merz Pharma Group had entered into a definitive agreement with Neocutis to acquire the company’s cosmetics and physician dispensed skin care business. The acquisition of Neocutis is a move that is hopefully going to strengthen and boost Merz’s market position in the field of aesthetics and reflects the company’s strategy to establish itself as a global leader in the medical and aesthetic dermatology.

Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in medical and aesthetic dermatology, and neurology in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology. Our future is promising, and we are committed to advancing new therapeutic options and improving patients’ lives. For more than 100 years, the development of Merz products has been based on our commitment to providing innovative medical approaches that earn trust of patients, physicians and partners worldwide. Merz’s business activities are in the research, development and distribution of innovative pharmaceutical and medical products for aesthetic and medical dermatology and the fields of neurology and metabolic disorders. Memantine, the first active agent in the world with a glutamatergeric effect for the treatment of moderate to severe Alzheimer’s dementia, is the second most frequently prescribed anti-dementive medication.

For the treatment of neurological movement disorders, Merz developed Xeomin® (incobotulinumtoxinA). Another core competence of Merz is clinical and aesthetic dermatology. Merz Aesthetics offers a well-balanced range of products for minimally invasive treatments. With the fillers Radiesse® Volumizing Filler and Belotero Balance® and the neurotoxin Xeomin® (incobotulinumtoxinA) the company is an important contributor to the American aesthetic market.  “Neocutis is an innovative company with an excellent presence in the U.S. market, and a promising potential for development,” said Philip Burchard, CEO of Merz Pharma Group. “This transaction is an important step to expand our U.S. business, as Neocutis products are an excellent addition to our own aesthetics portfolio.” “The acquisition of Neocutis significantly strengthens Merz’s presence in the U.S. aesthetics market,” said Bill Humphries, President and CEO of Merz North America, Inc. “Neocutis’ line of topical skin care products complements our current portfolio of aesthetic injectable products and expands our ability to provide patients and physicians with innovative, high-quality aesthetic products along the full continuum of care. We are excited to welcome the Neocutis team to the Merz family; we look forward to learning from them and seeing their contributions to our continued growth in North America. We are proud to contribute to Merz’s global leadership in aesthetic and medical dermatology, and we remain committed to growing the U.S. business via both organic growth and additional licensing and acquisition opportunities.”

Visit and check out the full line of Neocutis products available, priced competitively, always guaranteed authentic.